The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy.
Anna C. Ferrari
No relevant relationships to disclose
Mark N. Stein
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Alejandro Gomez-Pinillos
No relevant relationships to disclose
Donna D. Catamero
No relevant relationships to disclose
Tina M. Mayer
No relevant relationships to disclose
Fiona Collins
No relevant relationships to disclose
Tomasz M. Beer
No relevant relationships to disclose
Robert S. DiPaola
No relevant relationships to disclose